Emile Nuwaysir, Ensoma CEO

On in vi­vo cell ther­a­py quest, Take­da-backed En­so­ma buys a CRISPR up­start and bags $85M

Cell ther­a­py biotech En­so­ma made an all-stock ac­qui­si­tion of Dan­ish CRISPR tech­nol­o­gy up­start Twelve Bio, and al­so raised an $85 mil­lion Se­ries B.

The Boston …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.